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Abstract
Genetic variants of the methylenetetrahydrofolate reductase (MTHFR) gene involved in homocysteine
metabolism may be important predictors of antipsychotic drug-induced weight gain (AIWG). We tested whether
two functional MTHFR polymorphisms are related to AIWG. Weight gain was studied in two cohorts of
first-episode, initially drug-naive schizophrenia patients; Chinese Han (n=182) and Spanish Caucasians (n=72)
receiving antipsychotics for 10 wk and 3 months respectively. Blood DNA was genotyped for 677C/T and
1298A/C MTHFR polymorphisms. Patients with the 677 CC genotype had a significantly greater increase in
BMI compared to T-allele carriers in both Chinese (p=0.012) and Spanish (p=0.017) samples. The 677C/T
MTHFR polymorphism showed an additive effect, but no significant interaction, with the -759C/T HTR2C
polymorphism previously associated with AIWG.
These results suggest that the 677C/T MTHFR polymorphism might, along with the -759C/T HTR2C poly-
morphism and other genetic factors, provide a useful marker for the important and limiting side effect of AIWG.
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Introduction
Schizophrenia is a severe, complex and chronic disorder,
which for many patients is inadequately treated. Anti-
psychotic drugs can, in many individuals, relieve the
positive psychotic symptoms but have various adverse
effects; notably several of the drugs can induce a substan-
tial weight gain in susceptible individuals. This weight
gain may not only increase treatment noncompliance,
but also affect morbidity from metabolic consequences
including lipid abnormalities, insulin resistance and dia-
betes mellitus (Henderson et al., 2000). Patients receiving
antipsychotic treatment can develop metabolic abnor-
malities with increased risk of cardiovascular disease
and mortality (Casey et al., 2004; De Hert et al., 2009).
Susceptibility to antipsychotic-induced weight gain
varies substantially between individuals in ways that can-
not be fully explained by differences between drug effects
or other environmental factors. Thus genetic influences
are strongly implicated, and associations between
many genetic polymorphisms and antipsychotic-induced
weight gain have been reported. The most consistently
reported genetic factors involved in antipsychotic-
induced weight gain include polymorphisms in genes
for 5-hydroxytryptamine 2C (5-HT2C), 5-HT2A, adrener-
gic alpha 2A and melanocortin 4 receptors, as well as
leptin and fat mass and obesity associated (FTO) genes
(Reynolds, 2012).
Recently, genetic variants of the methylenetetra-
hydrofolate reductase (MTHFR) gene have been pro-
posed as potential predictors for antipsychotic-induced
metabolic side effects (Kuzman and Müller, 2012).
MTHFR exerts an important role in folate and homo-
cysteine metabolism by catalysing the reduction of
5,10-methylenetetrehydrofolate to 5-methylenetetrahy-
drofolate (5-MTHF), which is used in methionine syn-
thesis from homocysteine. The methionine is further
converted to S-adenosylmethionine (SAM), which is a
major methyl donor in a wide variety of enzymatic pro-
cesses including the methylation of DNA. MTHFR de-
ficiency can increase serum homocysteine, whereas the
decrease in 5-MTHF and SAM causes deficits in DNA
methylation, DNA synthesis and repair, and may
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predispose to neurodevelopmental and oncogenic pro-
cesses, resulting in the development of many disorders
including cardiovascular disease, renal failure, cancer
and congenital abnormalities (Ueland et al., 2001).
The association of MTHFR polymorphisms with meta-
bolic syndrome has been reported in the general popu-
lation. Obesity has been associated with MTHFR
1298A/C (Terruzzi et al., 2007) and 677C/T genotypes
(Lewis et al., 2006). Carriage of the 677T allele is asso-
ciated with insulin resistance (Chen et al., 2010;
Lunegova et al., 2011). Association of the 677T allele
with central obesity, hypertriglyceridemia and low levels
of high-density lipoprotein cholesterol (HDL-C) was also
reported in the latter study (Lunegova et al., 2011). A
replicated study reported that the 677T allele but not
the 1298A/C polymorphism of MTHFR was associated
with a greater risk of developing metabolic syndrome
and the TT genotype was associated with risk of insulin
resistance with greater central adiposity induced by anti-
psychotic treatment (Ellingrod et al., 2008, 2012). Others
have reported the association of metabolic syndrome in
schizophrenia with the 1298A/C polymorphism in 518
Caucasian patients (van Winkel et al., 2010a). These
authors also reported that the 1298C variant was asso-
ciated with an increased weight and impaired glucose
tolerance in 104 Caucasian patients who received antipsy-
chotic treatment for 3 months (van Winkel et al., 2010b).
In the present study, we examined the association of
the MTHFR 677C/T and 1298A/C polymorphisms with
antipsychotic-induced weight gain in first-episode
drug-naive patients with schizophrenia.
Methods
Study population
Two cohorts of first-episode, initially antipsychotic
drug-naive patients with schizophrenia receiving
treatment according to normal clinical practice were
studied; one main sample of Chinese Han (n=182) and
a replication sample of Spanish Caucasians (n=72). All
patients gave written informed consent to the procedure
of the study, which was approved by local ethical
committees. Height and weight to determined body-
mass index (BMI) were measured on initiation of anti-
psychotic drug treatment and after 8 or 10 wk (Chinese
cohort) or 3 months (Spanish cohort) and weight gain
was determined by change in BMI over the treatment
period. Initial antipsychotic drug treatment for Chinese
Han patients consisted primarily of chlorpromazine
(n=60) risperidone (n=114); eight patients received cloza-
pine, fluphenazine or sulpiride. Patients in the Spanish
cohort received primarily risperidone (n=21) or olanza-
pine (n=22) and two received both; others had quetiapine
(n=10), haloperidol (n=8) or ziprasidone (n=6) with three
not receiving antipsychotics. In this group, as with a sub-
sample of the Chinese cohort (Reynolds et al., 2002),
association of the -759C/T polymorphism of HTR2C
with weight gain had previously been identified
(Templeman et al., 2005). These results were also included
in a combined analysis with the MTHFR findings.
Genotyping of MTHFR polymorphisms
Genomic deoxyribonucleic acid (DNA) was isolated from
blood using standard techniques and was genotyped for
MTHFR 677C/T (rs1801133) and 1298A/C (rs1801131)
using TaqMan® SNP genotyping assays: assay ID
C_1202883_20 and C_850486_20, respectively (Applied
Biosystems, USA). The PCR conditions consisted of initial
denaturation at 95 °C for 10min, followed by 40 cycles of
95 °C for 15 s and 60 °C for 1min. Assays were run on a
Step One Plus Real-Time PCR System (Applied
Biosystems, USA).
Statistical analysis
All statistical analysis of results was performed using
SPSS version 18.0. Data were expressed as mean±S.D.
Stepwise linear regression was used to determine the po-
tential confounding effects of baseline BMI and age on
antipsychotic-induced weight gain. Analysis of variance
was used to determine the association between MTHFR
genotypes and weight gain. Statistical significance was
assumed for p values less than 0.05. The main Chinese co-
hort of 182 subjects had approximately 90% power to
identify a significant genotype difference for a medium
effect size of 0.5.
Results
Clinical characteristics and genotype results
The 182 (83 men, 99 women) Chinese Han patients had a
mean age 26.24±7.35 years. The genotype distribution for
677C/T MTHFR was as follows: CC (n=54), TT (n=28),
and CT (n=94), six samples failing genotyping, and for
1298A/C was AA (n=114), CC (n=5), and AC (n=56)
with seven samples failing genotyping. On regression
analyses, baseline BMI but not age had a significant con-
founding effect on weight gain after 8–10 wk treatment
(F=24.189, p<0.001), whereas age had a significant con-
founding effect on baseline BMI (F=11.036, p=0.001).
Therefore, the subsequent analyses were performed
with adjustment for age or baseline BMI as covariates.
The second study sample of 72 (53 men, 19 women)
Spanish patients had a mean age of 25.35±6.80 years.
The 677C/T genotype distribution was CC (n=20), TT
(n=13), and CT (n=36) and the 1298A/C genotypes
were AA (n=45), CC (n=3), and AC (n=21) with three
samples failing genotyping. On regression analysis, age
but not baseline BMI had a significant confounding effect
on weight gain at 3 months (F=7.026, p=0.010). Therefore,
the subsequent analysis was performed with adjustment
for age as a covariate.
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The two polymorphisms were found to be in strong
linkage disequilibrium (D′=0.866 and 1.00, r2=0.127 and
0.198 in Chinese and Spanish groups respectively) in
which the 677T allele was almost exclusively carried
with the 1298A allele.
Association of MTHFR 677C/T and 1298A/C
polymorphisms with weight gain
As shown in Table 1, the baseline BMI, age, and gender
distribution of both samples were not significantly differ-
ent between genotypes of the 677C/T MTHFR poly-
morphism. The CC genotype had greater changes in
BMI than T allele carriers: 1.58±1.25 vs. 1.04±1.16 kg/m2
in Chinese (p=0.012) and 2.86±1.53 vs. 2.02±1.54 kg/m2
in the Spanish sample (p=0.017) (Fig. 1).
Dividing the Spanish cohort into patients who received
or did not receive olanzapine, and the Chinese cohort into
those receiving either risperidone or chlorpromazine,
resulted in the absence of a significant drug×MTHFR
genotype interaction.
The baseline BMI, age, and gender distribution of both
study populations were not significantly associated with
the 1298A/C MTHFR polymorphism. Nor were the
changes in BMI of either study population significantly
different between 1298A/C AA genotype and C carriers:
1.27±1.24 vs. 1.08±1.17 kg/m2 in Chinese Han samples
(p=0.242) and 2.18±1.66 vs. 2.40±1.45 kg/m2 in Spanish
samples (p=0.621) respectively.
Gene–gene interaction
Previous findings in these two cohorts (Reynolds et al.,
2002; Templeman et al., 2005) showed that the T allele of
the 5-HT2C receptor gene (HTR2C) -759C/T polymorph-
ism had a protective effect against antipsychotic-induced
weight gain. Association of this polymorphism with
changes in BMI were as follows: in the Chinese cohort T
carriers 0.71±1.11 kg/m2 (n=38), C/CC genotype 1.33±
1.21 kg/m2 (n=141) p=0.004; in the Spanish cohort T car-
riers 1.24±1.46 kg/m2 (n=16), C/CC genotype 2.48±1.54
kg/m2 (n=50) p=0.012. The relationship between the
effects of the HTR2C -759C/T and the MTHFR 677C/T
polymorphisms was investigated. Analysing the associ-
ation of weight gain with both polymorphisms together
in each cohort, no significant interaction between the
Table 1. Sociodemographics, baseline bodymass index (BMI) and change in BMI amongmethylenetetrahydrofolate reductase (MTHFR)
677C/T and 1298A/C genotypes in Spanish and Chinese Han samples. Data are expressed as Mean±S.D.
MTHFR 677C/T genotype MTHFR 1298A/C genotype
CC CT TT p* AA AC CC p*
Chinese Han sample n=54 n=94 n=28 n=114 n=56 n=5
Age 25.04±6.84 26.21±7.18 28.45±8.60 0.136 26.54±7.77 25.61±6.61 27.20±5.54 0.710
Gender M/F (%male) 25/29 (46.3%) 57/65 (46.7%) 13/15 (46.4%) 0.998 53/61 (46.5%) 24/32 (42.9%) 4/1 (80%) 0.279
Baseline BMI (kg/m2) 20.99±2.69 21.43±2.77 21.92±3.53 0.607 21.47±3.06 21.20±2.59 21.78±1.51 0.895
Change BMI (kg/m2) 1.58±1.25 0.92±1.15 1.43±1.10 0.003 1.27±1.24 1.04±1.18 1.63±0.94 0.228
Spanish sample n=20 n=36 n=13 n=45 n=21 n=3
Age 27.60±8.34 24.25±5.69 23.92±6.96 0.168 25.36±7.36 24.76±6.38 25.00±1.73 0.949
Gender M/F (%male) 14/6 (70.0%) 29/7 (80.6%) 9/4(69.2%) 0.578 32/13 (71.1%) 17/4 (81%) 3/0(100%) 0.412
Baseline BMI (kg/m2) 21.44±3.78 22.06±3.70 22.29±4.01 0.780 21.92±3.62 21.99±4.16 21.45±3.76 0.973


































CC CT/TT CC CT/TT
p=0.017 p=0.012
Fig. 1. The association between methylenetetrahydrofolate reductase (MTHFR) 677C/T genotype and weight gain for Spanish
(a) and Chinese Han (b) schizophrenia patients. Data are expressed as mean±S.E.M. BMI: body mass index.
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polymorphisms was detected but a significant overall
effect was observed (p=0.001 in the Chinese sample;
p=0.019 in the Spanish sample), indicating an additive
effect of the two polymorphisms. Thus carriage of two
risk factors (HTR2C C/CC genotype and MTHFR 677
CC genotype) was associated with mean gains of 3.23
and 1.81 kg/m2 in Spanish (n=14) and Chinese (n=41)
cohorts respectively; equivalent values for subjects
carrying neither risk factor were 1.35 (n=10) and 0.63
(n=25) kg/m2.
Discussion
This study indicated that MTHFR 677C/T polymorphism
is associated with antipsychotic-induced weight gain
in first-episode patients with schizophrenia. Individuals
carrying the T allele showed less weight gain compared
to the common CC genotype after 8–10 wk or 3 months’
treatment with antipsychotic drugs. This finding,
observed in two patient cohorts of different ethnicity,
indicates the effect to be a robust and reproducible one.
The study had 90% power to identify a medium (0.50)
effect size in the main cohort; previous studies of associ-
ation of the well-replicated -759C/T polymorphism of
HTR2C with antipsychotic drug-induced weight gain in
a subgroup of the Chinese sample and in the Spanish
sample have demonstrated substantially larger effect
sizes of 0.90 and 0.86 respectively (Reynolds et al., 2002;
Templeman et al., 2005). In order for pharmacogenetic
risk factors to explain a good proportion of the variance
and thereby to have substantial predictive value, strong
effects are needed. In this we are aided substantially by
the cohorts studied here; each only included first-episode
patients who had never previously received antipsychotic
drug treatment. This eliminates much of the variance
associated with prior drug treatment, which can induce
significant weight gain within a few weeks of initial treat-
ment (Zhang et al., 2004).
The absence of an effect in the 1298A/C polymorphism,
despite it being in strong linkage disequilibrium (high D′
values) with the significantly associated 677 genotype,
presumably relates to the large differences in allele fre-
quency between the two polymorphisms, as reflected by
low r2 values.
In two previous cross-sectional studies the 677C/T
polymorphism is associated with metabolic syndrome
following antipsychotic drug treatment (Ellingrod et al.,
2008, 2012), although these authors find the 677T allele
to be a risk factor, whereas we find a consistent effect of
the 677T allele in protecting against antipsychotic
drug-induced weight gain. This may well indicate the dif-
ference between effects on initial weight gain and its long-
term consequences, in which differing pharmacogenetic
influences are apparent (Reynolds et al., 2013). In another
study the 1298A/C but not 677C/T polymorphism was
associated with metabolic syndrome in schizophrenia
(van Winkel et al., 2010a). The one previous longitudinal
study of changes in weight and metabolic parameters fol-
lowing 3 months’ treatment with second-generation anti-
psychotics also found an association with the 1298A/C
but not 677C/T polymorphism (van Winkel et al.,
2010b). This study differed from the present investigation
of first-episode drug-naive patients in that weight but
not BMI was measured, and the 104 patients were older
(mean 31.3 yr) with first admission on average over 6yr
previously; thus prior treatment may well have con-
founded subsequent weight gain. However, their
finding that the 1298A allele is associated with less weight
gain is not inconsistent with our finding given the close
linkage disequilibrium between the two polymorphisms
studied. As discussed by van Winkel et al. (2010b),
there are no clinical or ethnic factors identified that may
be responsible for the discrepancies between these
findings, although it is notable that most studies were
not powered to identify significant differences between
the effects of the two closely linked polymorphisms.
Nevertheless these various reports all indicate that func-
tional genetic variation in MTHFR can influence antipsy-
chotic drug-induced weight gain.
It is conceivable that pharmacogenetic associations
such as that identified here may vary depending on the
treatment regime. Different drugs may have differing
mechanisms underlying their effect on body weight – cer-
tainly the greater effect of olanzapine over risperidone
and several other antipsychotics supports this – and
these pharmacological mechanisms may be differentially
influenced by genetic polymorphisms. Our study was
not powered to subdivide samples into treatment sub-
groups; however, further work needs to address the poss-
ible drug specificity of such pharmacogenetic findings.
There was no significant interaction between -759C/T
of HTR2C and 677C/T of MTHFR on antipsychotic-
induced weight gain, indicating that both polymorphisms
exert independent influences on this side effect. However,
the gene–gene analysis resulted in substantial increases in
statistical significance, demonstrating an additive effect of
the two polymorphisms. Clearly there are other genetic
influences that are likely to contribute to determining
initial weight gain associated with antipsychotic drug
treatment, including polymorphisms for genes for
leptin, melanocortin receptor 4, adrenoreceptor alpha2A
and g-protein beta3 among probably many others
(Reynolds, 2012).
The exact mechanism by which MTHFR polymorph-
isms might contribute to determining antipsychotic
drug-induced weight gain is unclear. Both variant alleles
of 677C/T and 1298A/C MTHFR polymorphisms cause
decreased enzyme activity (Weisberg et al., 1998),
although it is not easy to distinguish effects of two
closely linked polymorphisms in vivo. MTHFR is an im-
portant enzyme in one-carbon metabolism and, via its
role in DNA synthesis and methylation (Sugden, 2006),
may influence gene expression (Jirtle and Skinner, 2007);
such epigenetic effects could be involved in antipsychotic
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drug-induced weight gain. Diminished levels of genomic
DNA methylation (Stern et al., 2000) and gene-specific
DNA methylation (Burghardt et al., 2012) have been
reported to be associated with the 677TT genotype. It is
therefore possible that decreased MTHFR enzyme activity
in 677TT genotype results in decreased DNA methylation
of genes involved in body weight regulation.
DNA methylation status is influenced by gene–nutri-
ent interaction. It has been suggested that the MTHFR
677TT genotype affects DNA methylation status through
an interaction with folate status (Friso and Choi, 2002).
These authors found that genomic DNA methylation in
peripheral blood mononuclear cells was directly corre-
lated with folate status, inversely correlated with homo-
cysteine levels, and only 677TT subjects with low folate
accounted for decreased DNA methylation (Friso et al.,
2002). Thus folate status in addition to the 677C/T
MTHFR polymorphism might modulate DNA methyla-
tion of genes relating to the regulation of food intake,
energy expenditure or body weight regulation, and thus
could be an unexplored factor contributing to the vari-
ance in this and previous studies.
In conclusion, this present study indicates the associ-
ation of the MTHFR 677C/T single polymorphism with
weight gain following initial antipsychotic drug treat-
ment in first-episode psychotic patients. Furthermore,
the effect of the 677T allele appears to have a protective
effect additional to that of the well-established HTR2C
-759T allele against antipsychotic-induced weight gain.
These two polymorphisms, in addition to several other
possible genetic factors, might be valuable as pharmaco-
genetic markers of this important and limiting side effect.
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